REVIEW

Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old [version 1; peer review: 3 approved]

Alberto Falchetti^{1,2}

¹EndOsMet Unit, Villa Donatello, Piazzale Donatello 2, Florence 50100, Italy

²Hercolani Clinical Center, Via D'Azeglio 46, Bologna 40136, Italy

V1 First published: 24 Jan 2017, 6(F1000 Faculty Rev):73
<https://doi.org/10.12688/f1000research.7230.1>

Latest published: 24 Jan 2017, 6(F1000 Faculty Rev):73
<https://doi.org/10.12688/f1000research.7230.1>

Abstract

Despite its identification in 1997, the functions of the *MEN1* gene—the main gene underlying multiple endocrine neoplasia type 1 syndrome—are not yet fully understood. In addition, unlike the *RET*—MEN2 causative gene—no hot-spot mutational areas or genotype–phenotype correlations have been identified. More than 1,300 *MEN1* gene mutations have been reported and are mostly "private" (family specific). Even when mutations are shared at an intra- or inter-familial level, the spectrum of clinical presentation is highly variable, even in identical twins. Despite these inherent limitations for genetic counseling, identifying *MEN1* mutations in individual carriers offers them the opportunity to have lifelong clinical surveillance schemes aimed at revealing MEN1-associated tumors and lesions, dictates the timing and scope of surgical procedures, and facilitates specific mutation analysis of relatives to define presymptomatic carriers.

Keywords

Multiple Endocrine Neoplasia Type 1 Syndrome , Menin , familial MEN1 , genetic screening MEN1 , MEN1 gene mutation ,

Open Peer Review

Approval Status

	1	2	3
version 1			
24 Jan 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Antongiulio Faggiano**, University of Naples Federico II, Naples, Italy
Annamaria Colao, University of Naples Federico II, Naples, Italy
2. **Eitan Friedman**, Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel
 Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3. **Arundhati Sharma**, All India Institute of

Medical Sciences, New Delhi, New Delhi, India

Any comments on the article can be found at the end of the article.

Corresponding author: Alberto Falchetti (alberto.falchetti2@alice.it)

Competing interests: The author declares that he has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Falchetti A. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Falchetti A. **Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):73 <https://doi.org/10.12688/f1000research.7230.1>

First published: 24 Jan 2017, 6(F1000 Faculty Rev):73 <https://doi.org/10.12688/f1000research.7230.1>

Introduction

Multiple endocrine neoplasia type 1 syndrome (MEN1, MIM*131100) is an autosomal dominant disorder in which varying combinations of either endocrine or non-endocrine tumors may present extremely varied phenotypic clinical patterns. Considerable phenotypic variability of tumor type manifestations and age at diagnosis has been reported, even within the same family, whose affected members share the same, inherited, *MEN1* gene mutation¹.

The original description of the classical “P-triad” corresponds to parathyroid, pituitary, and pancreatic (neuro)endocrine tumors². Other MEN1-associated endocrine (adrenocortical tumors and carcinoids) and non-endocrine, mostly benign, neoplasms (facial angiofibromas, collagenomas, and others) may also occur^{3,4}, and other types of tumors (e.g. adrenal) are occasionally reported in the literature. Despite the frequent occurrence of endocrine neoplasm combinations, findings so far suggest that a genetically predisposed abnormal proliferative control may exist in practically all of the mutant cells of a MEN1-affected individual.

Much of the well-established knowledge on MEN1 has been already described in my previous F1000 Faculty review⁵; however, information on new aspects is lacking. In this short review, attention to the role of genetics in the clinical management of MEN1-affected subjects will be presented, including also some new technical and practical aspects.

Mendelian genetics of MEN1 syndrome

The estimated worldwide prevalence of MEN1 is expected to be between 1 in 30,000 and 1 in 500,000^{3,6}, but some geographical clustering due to founder effects has also been reported^{7,8}. MEN1 syndrome may occur in either familial or sporadic forms. The sporadic form of MEN1, where only one affected person is identified in a previously unaffected family, is observed much less frequently (10% of cases) than the familial form (90% of cases).

MEN1 is clinically defined when at least two first-degree relatives have a combination of either one of the three main endocrine tumors. Alternatively, it involves only one of the main target organs and a *MEN1* disease-causing germline mutation. As MEN1 syndrome follows an autosomal dominant inheritance pattern, the offspring of an affected mutation carrier has a 50% chance of inheriting the pathogenic mutation⁹. As already mentioned, it is not only members of the same family who may have diverse clinical features but also MEN1 monozygotic twins who have been reported to exhibit differing symptoms¹⁰. However, the distinction between sporadic and familial cases is not always easy. In some sporadic cases, where family history cannot be ascertained, this may be attributed to non-paternity, early parental death, lack of careful family assessment, and adoption¹¹.

MEN1 penetrance is high, with more than 95% of *MEN1* mutation carriers having biochemical evidence of MEN1—generally represented by mono- or pluri-hormones over secretion—with 100% presenting with hyperparathyroidism by 50 years of age and approximately 80% of patients presenting clinical signs by the fifth decade of life¹² (Table 1). In fact, patients with MEN1-related primary hyperparathyroidism (PHPT) exhibit a higher susceptibility

Table 1. Age-related penetrance by 50 years of age for “classical” MEN1-associated tumors^{60,63}.

MEN1-associated endocrine disorder	Age-related penetrance by 50 years of age
Primary hyperparathyroidism (multiglandular disease)	73–75%
Pituitary adenomas	31–48%
Islet cell tumors*	45–49%

*This classification considers only the “old, classical” functioning pancreatic endocrine tumors, as originally described in the literature, but currently with the widespread use of endoscopic ultrasound in the work up of MEN1, duodenal-pancreatic neuroendocrine tumors, mostly nonfunctioning, are found in more than 80% of patients and their early occurrence has also been demonstrated^{13–15}. However, the age of presentation of specific tumor types is highly variable, ranging from 9–25 years of age for the youngest diagnosed case to 68–77 years for the oldest case with a tumor manifestation⁶⁰.

to nephrolithiasis than do non-MEN1-PHPT patients^{13–15}, as there is also a higher frequency of renal calculi in MEN1 patients before 30 years of age¹⁶.

The *MEN1* gene and its encoded product, menin

The *MEN1* gene localizes to chromosome 11q13^{17–19} and consists of 10 exons encoding a 610-amino-acid protein called menin. Menin is ubiquitously expressed and is predominantly located in the nucleus in non-dividing cells^{20–24}.

Menin is extremely functionally versatile. It shows no homology with other known proteins and the mechanism by which its loss of function leads to MEN1 is still unclear^{20–22}. Menin primarily localizes to the nucleus; it contains two classical nuclear localization signals (NLSs) and at least one further non-classical NLS in its C-terminus^{23,24}. At the nuclear level, menin can associate with chromatin²⁵, double-stranded DNA²⁶, the lysine-specific histone methyltransferases KMT2A and KMT2B^{27,28}, and components of a transcriptional repressor complex, including histone deacetylases (HDACs)²⁹.

Menin interacts with transcription factors, such as activating protein-1 (AP-1), JunD, nuclear factor-κB (NF-κB), β-catenin, mothers against decapentaplegic (SMAD) family members, and estrogen receptor α (ERα)^{27,30–36}. It is also able to bind to cytoskeletal proteins, such as vimentin³⁷, and cytoplasmic cell signaling mediators, including Akt1/protein kinase B (PKB) and Forkhead box protein O1 (FoxO1)^{38,39}. In addition, it has been shown that menin plays a role in cell proliferation^{40–42}, apoptosis^{43,44}, and genome integrity⁴⁵.

The menin/KMT2A complex also regulates the expression of several Hox genes as well as *CDKN1B*, a gene that harbors inactivating mutations accounting for multiple endocrine neoplasia type 4 (MEN4) syndrome (MIM #610755). The same protein complex interacts with ERα and co-activates ERα-mediated transcription^{27,36,46,47}. KMT2A, located at 11q23.3 chromosome, harboring recurrent chromosomal breakpoints, is disrupted in distinct 11q23 recurrent

chromosomal translocations⁴⁸. Its rearrangement alleles encode mixed-lineage leukemia (MLL) fusion proteins (MLL-FPs) or internal gene rearrangement products. Interestingly, chromosomal rearrangements involving KMT2A lead to MLL, and, in this context, menin was shown to be required for KMT2A-dependent oncogenic transformation⁴⁹. Some authors have produced robust data showing that combining two targeted treatments, DOT1L (H3K79 methyltransferase) and menin inhibition, may result in a promising therapeutic strategy for MLL-rearranged leukemia^{50,51}.

The functional versatility of menin in different tissues may be key in unraveling the as-yet-unexplained tissue selectivity of MEN1-associated tumors as well as the variable phenotypic expression of an identical mutant allele.

Genetic testing and screening in MEN1

Although MEN1 is a rare disorder, the autosomal dominant inheritance form implies that detecting a germline *MEN1* mutation in a single familial member has important implications for other family members. In particular, first-degree relatives have a 50% risk of possessing the familial mutation with the consequent high risk for developing MEN1-associated tumors¹. Thus, screening for MEN1 involves both clinical and imaging detection of associated tumors and ascertainment of their germline genetic state: normal or mutant gene carrier⁵². Cloning of the *MEN1* gene²⁰ facilitated the identification of asymptomatic mutation carriers, who are genotypically assigned a high-risk status for developing MEN1-associated tumors and are offered an early detection scheme⁵.

Moreover, a potentially “new” MEN1 family could also be identified when it first appears in a subject lacking a clear familial history. Thus, affected relatives have the opportunity to be included in a specific surveillance schedule and receive therapy as soon as possible⁵³.

Linkage analysis approach: it cannot be considered totally obsolete

In the past, before cloning the *MEN1* gene in 1997^{20,21}, linkage analysis was the only clinically useful approach for genetic diagnosis; it uses highly polymorphic DNA markers located upstream and downstream of 11q13, the chromosomal region to which the *MEN1* gene was mapped^{17–19}. Since some of these DNA markers show no recombination with the *MEN1* gene (i.e. PYGM, D11S463, and D11S427), an accuracy of up to 99.5% could be reached in the test for carriers, with incorrect results due to meiotic crossing over being omitted^{5,21}. However, for such analysis, there needs to be a MEN1 family with two or more living, clinically affected members, bridging two or more generations, allowing for the detection of the family-specific 11q13 risk haplotype in affected people⁵³.

One obvious limitation is genetic heterogeneity with an overlap between MEN1 and MEN4. Another important limitation of this screening technology is that it cannot be applied to a single index case. However, the linkage approach should be considered when mutational analysis fails to detect any germline *MEN1* mutation in a proband and the pedigree is informative (more affected members from different generations).

Finally, it has been also reported that applying forensic techniques to analyze ancient DNA enables the identification of the familial disease-associated haplotype, demonstrating that even when one or more relatives are no longer living, the family history relating to MEN1 can still be assembled⁵⁴.

Mutations of the *MEN1* gene

In the 10 years following the identification of the *MEN1* gene, a total of more than 1,300 mutations (approximately 85% germline and 15% somatic) were characterized⁵⁵, with the current total number of mutations at over 1,800 (<http://www.umd.be/MEN1/>⁵⁶). The germline *MEN1* mutations consist of 459 different mutations, which are distributed throughout the whole 1830 bp coding region and splice sites of the *MEN1* gene^{20,21,57–59} (Table 2).

However, around 5–10% of MEN1-affected individuals may not harbor mutations in the *MEN1* gene coding region^{20,21,57–60}; they may have whole gene deletions or mutations in the promoter or untranslated regions that have not been reported to date. Large deletions will not be easy to detect by conventional Sanger sequencing, but next-generation sequencing (NGS) technology enables us to extrapolate the large gene rearrangements. No studies that have employed these novel techniques in *MEN1* gene analysis have been published yet.

Approximately 75% of *MEN1* mutations are inactivating⁵⁵, as expected for a tumor suppressor gene. There are many different types of mutations, and they are dispersed throughout the coding region of the gene rather than being clustered, as predicted from pathogenic mutations in a tumor suppressor gene. A few of the mutations have occurred a number of times in unrelated families, and mutations at nine sites in the *MEN1* gene account for over 20% of all of the germline mutations (Table 3).

These recurring mutations could signify possible “hot spots”, and the deletional and insertional hot spots may correlate with DNA sequence repeats, DNA stretches of long strips of either single nucleotides or shorter repeat elements, ranging from dinucleotides to octanucleotides⁵⁹. Thus, a replication-slippage model could be in place at different codons, meaning that the *MEN1* gene seems to include DNA sequences that may make it prone to deletional

Table 2. Different types of *MEN1* gene mutations reported in the literature and their frequencies⁵⁷.

Types of <i>MEN1</i> gene mutations	Percentage
Nonsense	23%
Frameshift deletions or insertions	41%
In-frame deletions or insertions	6%
Splice site	9%
Missense	20%
Whole gene or particular gene deletions	1%

Table 3. The nine recurring mutations by type^{55,56}.

Type of <i>MEN1</i> mutations	Localization within the gene (there is more than one mutation in most of each of the following codons)
Deletions or insertions	Codon 83
	Codon 84
	Codon 120
	Codons 210–211
	Codons 514–516
Novel acceptor site	Intron 4
Nonsense	Arg98Stop
	Arg415Stop
	Arg460Stop

and insertional mutations⁵⁹. There is no evidence that the promoter region of the *MEN1* gene contains any mutations, but this intriguing, albeit theoretical, possibility remains⁶¹.

What to do when a *MEN1* gene mutation is not detected at DNA sequencing: alternative approaches

In a relatively small percentage of patients with *MEN1* (5–10%), gene mutations in either the coding region or the splice sites of the *MEN1* gene are not identified⁵⁵. Consequently, it cannot be excluded that pathogenic sequence variants in the promoter, deep in the introns, or in the untranslated regions (gene regions normally not analyzed in “routine” genetic tests) may exist. In addition, gross deletion/insertion of parts of the gene or even the entire gene cannot be detected with classical *MEN1* Sanger sequencing analysis.

Southern blot analysis or other gene dosage procedures (e.g. array comparative genomic hybridization [CGH]) or NGS could be useful to detect “gross” alterations at the *MEN1* gene, such as large deletions, insertions, or other large genomic rearrangements involving the *MEN1* gene. Multiplex ligation-dependent probe amplification (MLPA) is a quantitative and very sensitive and accurate multiplex polymerase chain reaction-based approach that enables the detection of copy number changes within a specific gene. Therefore, it is also possible to reveal whole gene and/or entire exon losses as gross modifications at the intra-genic level. Diagnostic screening by MLPA should be considered in *MEN1* index cases in which we have a negative sequencing *MEN1* gene test result and large deletions/duplications of the *MEN1*-coding region which need to be assessed/excluded. As mentioned above, familial haplotype analysis should still be considered when either sequencing or MPLA screenings are negative⁶².

Attention to *MEN1* gene polymorphisms

Since 24 polymorphisms (12 in the coding region [10 synonymous and two non-synonymous], nine in the introns, and three in the untranslated regions) of the *MEN1* gene have been described⁵⁵, it is important to consider their occurrence, as they need to be

differentiated from mutations when mutational analysis for genetic diagnosis is performed.

MEN1 phenocopies

Finally, since less than 2% of clinical *MEN1* patients lack evidence of *MEN1* mutation, in cases where patients present with classic *MEN1* symptoms but negative results for *MEN1* and *CDKN1B* mutations, further investigation of genes encoding members of the cyclin-dependent kinase inhibitor (CDKN) family—such as *CDKN1A* (p21cip1), *CDKN2B* (p15Ink4b), or *CDKN2C* (p15Ink4c), which all negatively regulate cell cycle progression and cell growth⁵⁵—should be considered⁵³.

Genotype–phenotype correlations

There is no correlation between *MEN1* mutation location along the gene or the type of mutation and clinical manifestations. This lack of genotype–phenotype correlation, in addition to the sheer number of possible mutations in the coding region of the *MEN1* gene, results in greater difficulty for mutational analysis in the diagnosis of *MEN1* than in the diagnosis of *MEN2*¹⁰.

One noteworthy study found that all patients with *MEN1* frameshift mutations have PNETs⁶³, while another showed a higher rate of malignant tumors for mutations in *MEN1* gene exons 2, 9, and 10⁶⁴. However, no genotype–phenotype correlation could be consistently confirmed in other patient populations by other investigators^{12,55}. Moreover, studies of unrelated kindreds exhibiting the same *MEN1* mutation showed large variability of different associated tumors^{11,58}—as mentioned above, there are reports of identical twins who carry an identical *MEN1* mutation with different *MEN1* clinical phenotypes^{10,65,66}. Finally, whereas some families with particular *MEN1* mutations develop only isolated hyperparathyroidism, other families with the same mutations develop a full *MEN1* spectrum⁵⁵.

Has the mutational analysis of the *MEN1* gene improved the life expectancy associated with the syndrome?

Although *MEN1* patients have been reported to exhibit a decreased life expectancy, *MEN1*-associated mortality (Table 4), mostly due to gastroenteropancreatic malignancy^{12,67–70}, has improved since the 1980s owing to both early detection of asymptomatic/presymptomatic *MEN1* mutation carriers and more intense clinical screening programs, with an overall better perioperative survival, especially for neuroendocrine tumors (NETs) of the gastrointestinal tract, together with appropriate drug treatment, when applicable⁶⁹.

Table 4. Cause of death due to *MEN1*-associated malignancies. Patients affected by these malignancies have a threefold higher risk of death⁶⁹.

<i>MEN1</i> tumors with high risk of death	Percentage
Malignant neuroendocrine gastroenteropancreatic tumors (mainly gastrinomas) Thymic or bronchial carcinoid tumors	30–40%

Thus, the early genetic diagnosis of *MEN1* is strictly recommended in order to both identify patients before biochemical/clinical manifestations occur and improve long-term outcome. Periodical screening and clinical follow-up according to clinical guidelines have to be performed for all *MEN1* patients in order to offer appropriate and early medical/surgical interventions^{71,72}, and, more in general, it has also been suggested that early genetic screening for those syndromes in which NETs may occur as a hereditary feature may contribute to related morbidity/mortality reduction in asymptomatic subjects through better and more appropriate clinical management⁷³.

It seems that we can offer *MEN1* patients a better prognosis and a reduction in morbidity and mortality if early stage diagnosis of the tumor is achieved, along with presymptomatic tumor detection and early administration of specific therapy^{13–15}.

MEN1 tumorigenesis: not only loss of heterozygosity

Consistent with Knudson's two-hit hypothesis^{17,18,74}, the *MEN1* gene is thought to act as a tumor suppressor, since over 90% of tumors from *MEN1* patients exhibit loss of heterozygosity (LOH). However, intra-genic deletions and point mutations can also be responsible for inactivating the wild-type allele—the second hit. In fact, some *MEN1* tumors where no LOH was demonstrated have been shown to harbor different somatic and germline-inactivating point mutations of the *MEN1* gene⁷⁵, mechanisms still consistent with the Knudson two-hit hypothesis⁷⁶.

Any role for epigenetic and/or modifying genetic mechanisms in the clinical expression of *MEN1*?

Since it is known that menin is an essential component of histone methyltransferase complexes that contain members from the MLL and trithorax protein family²⁷, by acting as a scaffold protein, it may epigenetically regulate gene expression via histone methylation or acetylation. Consequently, it has also been suggested that epigenetic mechanisms triggered by environmental factors may influence the disease phenotype in patients carrying the same *MEN1* mutation⁷⁷. Moreover, as recently reported, a specific variant of the *CDKN1B* gene whose inactivating mutations account for the MEN4 syndrome was demonstrated to be disease modifying in *MEN1* patients with truncating *MEN1* mutations, causing a higher number of *MEN1*-related tumors⁷⁸.

Could microRNA molecules play a role in *MEN1* tumorigenesis? The miR-24 experience

It has been described that a microRNA molecule, miR-24-1, is able to bind to the 3' untranslated region of *MEN1* mRNA. miR-24-1 expression profiles have been conducted in some *MEN1* parathyroid adenomas from *MEN1* mutant carriers, their sporadic non-*MEN1* counterparts, and in normal parathyroid tissue. The results suggest that *MEN1* tumorigenesis may be under “negative feedback loop” control between miR-24-1 and menin, thus mimicking the Knudson's second hit and possibly buffering the effect of the stochastic factors hypothesized to contribute to the onset and progression of *MEN1* disease⁷⁹. If such findings are confirmed by other studies in other *MEN1* tumors from subjects with the same or different *MEN1* gene mutations, they could suggest the existence of an alternative pathway to *MEN1* tumorigenesis and, probably, to the ‘Knudson's

two-hits dogma or, maybe, an alternative *MEN1* tumorigenesis for specific *MEN1*-affected endocrine and non-endocrine tissues.

Overall, this could be considered as a new basis for future developments in RNA antagomir(s)-based strategies to control tumorigenesis in *MEN1* carriers.

Could variants in genes other than *MEN1* be disease modifying?

Recently, other genetic mechanisms have been investigated for their possible involvement in *MEN1*-related pleiotropic phenotypic expression. It is known that the p27^{Kip1} protein, encoded by the *CDKN1B* gene, is downstream of *MEN1*-driven tumorigenesis. Genotypic frequencies of the *V109G* variant of p27 have been evaluated in a cohort of *MEN1* patients and healthy controls and *V109G* seems to influence the clinical manifestation of adult *MEN1* patients carrying truncating *MEN1* gene mutations⁷⁸.

Since menin forms a transcriptional complex with MLL2 and RNA polymerase II, regulating p27^{Kip1} expression, inactivation of menin reduces p27-mRNA levels and a second hit event, as the occurrence of *V109G* variant, potentially correlated with p27 protein degradation by p38JAB1, a protein promoting the degradation of this cyclin-dependent kinase inhibitor, may trigger exaggerated multiple tumor developments.

More recently, it has been suggested that such a polymorphism may be associated with certain *MEN1* mutations (*c.502G>A*, *p.G168R* in exon 3, *c.673T>A*, *p.W225R* in exon 4, and *c.825 + 1G>A* in intron 5), and carriers of both the genetic variants, *MEN1* mutation and *V109G*, seem to exhibit a more aggressive clinical course of the syndrome with a worse prognosis⁸⁰.

All of the above reported findings need to be replicated in other, ethnically diverse *MEN1* clinical series.

Future perspectives in *MEN1* genetic analysis

Recent developments have seen a new era for sequencing in several Mendelian diseases in the form of NGS technology, which could be helpful for bypassing the limitations of “classical” genetic analysis, as described above. The NGS approach as a genetic diagnostic tool could permit simultaneous sequencing of the following extra-/intra-genic regions: a) regulating and untranslated, b) coding sequences, and c) introns. Thus, such an approach may allow the identification of either causative large intra-genic deletions/duplications or novel mutations⁸¹. Specifically, clinically relevant chromosomal rearrangements, such as the ones occurring at KMT2A (MLL), can be detected by targeted gene panel-based NGS that has a sensitivity and specificity equivalent to fluorescence *in situ* hybridization protocols, and reverse transcription polymerase chain reaction approaches, as well as more detailed information and better efficiency for molecular testing. Furthermore, translocation detection by NGS offers more advantages than the “conventional” laboratory methods, such as the more precise definition of the breakpoint region and the detection of both cryptic rearrangements and unknown molecular partner genes while it runs parallel with gene mutation detection⁸². Moreover, NGS could extend the sequencing of nucleotides from a single gene up to the multigene

level by specifically setting up targeted panels, up to the whole genome, producing huge amounts of genetic data on a gigabyte scale in a single step. NGS may represent a higher-throughput alternative to classical DNA sequencing as well as being less expensive when compared to the traditional method.

In addition, NGS is very flexible, reaching an adequate resolution level for any single genetic analysis, also considering that a sequencing run can be specifically tailored to obtain genetic data and/or to screen one or more predetermined genomic regions or a specifically desired gene set.

Laboratory protocols such as whole-exome sequencing (WES) and whole-genome sequencing (WGS) enable us to analyze an untargeted exome- or genome-wide section of an individual's DNA and, at least theoretically, detect every genetic variant in a subject. Such approaches in parent–offspring trio models may be helpful in determining inherited variants as well as *de novo* mutations in the offspring and will enhance our ability to identify most disease-causing genes contributing to sporadic monogenic disorders, such as MEN1 syndrome⁸³.

In summary, overall, two alternative protocols are currently available to detect gene mutations: (1) WES and WGS, facilitating the identification of disease-associated genes and/or regulatory elements, even those not previously known—this approach tends to be useful for genetically determined diseases whose responsible gene/genes are still unknown; and (2) NGS-targeted multi-gene sequencing by selecting a platform with specific genes comprising coding, non-coding, and regulatory gene regions.

Implementation of all of these procedures will facilitate, in the next few years, the genetic diagnosis of diseases or groups of related disorders, such as multiple endocrine neoplasia syndromes, making their differential genetic diagnosis possible by creating an up-to-date specific platform that includes all specifically relevant genes^{84,85}. In such a way, it will soon be possible to classify different human oncological disorders, including MEN1 syndrome, according to the underlying genotype rather than solely the biochemical/clinical phenotype. Thus, in the near future, it will be possible for

MEN1-affected subjects to have targeted medical consultations and interventions and engagement in gene-specific patient groups, as well as more appropriate treatments⁸³.

Current limitations and advantages in MEN1 genetic diagnosis

Limitations

Lack of genotype/phenotype correlation. As stressed here and in my previous F1000 Faculty review, we do not have any genotype–phenotype correlation. Thus, whether a specific *MEN1* mutation is detected and/or it localizes to a specific functional domain of menin still does not improve specific clinical predictions of disease occurrence, symptoms, or progression. Consequently, genetic information currently has limited importance in the individual clinical management of mutation carriers whether or not they are displaying symptoms.

Advantages

Identification of germline *MEN1* gene mutation. Clearly, the identification of a pathogenic *MEN1* mutation is useful for ensuring an individual's inclusion in clinical surveillance routines for MEN1-associated tumors and lesions⁵, suggesting specific surgical procedures, and identifying the need for specific mutation analysis of first-degree relatives to identify presymptomatic mutation carriers. In the presence of a germline *MEN1* mutation, lifelong specific clinical surveillance is suggested, as reported in the literature⁸⁶.

Competing interests

The author declares that he has no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgements

A warm thank you to all MEN1 patients and families who have actively cooperated with me over the years, always making themselves available for clinical and genetic research.

References

- Trump D, Farren B, Wooding C, *et al.*: **Clinical studies of multiple endocrine neoplasia type 1 (MEN1).** *QJM*. 1996; **89**(9): 653–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wermer P: **Endocrine adenomatosis and peptic ulcer in a large kindred. Inherited multiple tumors and mosaic pleiotropism in man.** *Am J Med*. 1963; **35**(2): 205–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Agarwal SK: **Multiple endocrine neoplasia type 1.** *Front Horm Res*. 2013; **41**: 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Marx S, Spiegel AM, Skarulis MC, *et al.*: **Multiple endocrine neoplasia type 1: clinical and genetic topics.** *Ann Intern Med*. 1998; **129**(6): 484–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Falchetti A: **Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how.** *F1000 Med Rep*. 2010; **2**: pii: 14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bartsch DK, Langer P, Rothmund M: **Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1.** *Wien Klin Wochenschr*. 2007; **119**(19–20): 602–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kytola S, Villablanca A, Ebeling T, *et al.*: **Founder effect in multiple endocrine neoplasia type 1 (MEN 1) in Finland.** *J Med Genet*. 2001; **38**(3): 185–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vierimaa O, Ebeling TM, Kytölä S, *et al.*: **Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation.** *Eur J Endocrinol*. 2007; **157**(3): 285–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brandi ML, Bordi C, Tonelli F, *et al.*: **Multiple endocrine neoplasia type 1.** In: *Principles of Bone Biology*. 3rd edition. Edited by Bilezikian JP, Raisz LG, Rodan

- GA. San Diego, CA USA: Academic Press, 2008; 2: 1345–74.
[Publisher Full Text](#)
10. Flanagan DE, Armitage M, Clein GP, *et al.*: Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. *Clin Endocrinol (Oxf)*. 1996; 45(1): 117–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Thakker RV: Multiple endocrine neoplasia—syndromes of the twentieth century. *J Clin Endocrinol Metab*. 1998; 83(8): 2617–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. **F** Machens A, Schaaf L, Karges W, *et al.*: Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. *Clin Endocrinol (Oxf)*. 2007; 67(4): 613–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 13. Lourenco DM Jr, Coutinho FL, Toledo RA, *et al.*: Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. *J Bone Miner Res*. 2010; 25(11): 2382–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Eller-Vainicher C, Chiodini I, Battista C, *et al.*: Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. *J Bone Miner Res*. 2009; 24(8): 1404–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Lamers CB, Froeling PG: Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA I). *Am J Med*. 1979; 66(3): 422–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Christopoulos C, Antoniou N, Thempeyioti A, *et al.*: Familial multiple endocrine neoplasia type I: the urologist is first on the scene. *BJU Int*. 2005; 96(6): 884–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Larsson C, Skogseid B, Oberg K, *et al.*: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. *Nature*. 1988; 332(6159): 85–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Friedman E, Sakaguchi K, Bale AE, *et al.*: Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. *N Engl J Med*. 1989; 321(4): 213–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Emmert-Buck MR, Lubensky IA, Dong Q, *et al.*: Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. *Cancer Res*. 1997; 57(10): 1855–8.
[PubMed Abstract](#)
 20. Chandrasekharappa SC, Guru SC, Manickam P, *et al.*: Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science*. 1997; 276(5311): 404–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Lemmens I, Van de Ven WJ, Kas K, *et al.*: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. *Hum Mol Genet*. 1997; 6(7): 1177–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Wautot V, Khodaei S, Frappart L, *et al.*: Expression analysis of endogenous menin, the product of the multiple endocrine neoplasia type 1 gene, in cell lines and human tissues. *Int J Cancer*. 2000; 85(6): 877–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Guru SC, Goldsmith PK, Burns AL, *et al.*: Menin, the product of the MEN1 gene, is a nuclear protein. *Proc Natl Acad Sci U S A*. 1998; 95(4): 1630–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. **F** La P, Desmond A, Hou Z, *et al.*: Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. *Oncogene*. 2006; 25(25): 3537–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 25. Jin S, Mao H, Schnepf RW, *et al.*: Menin associates with FANCD2, a protein involved in repair of DNA damage. *Cancer Res*. 2003; 63(14): 4204–10.
[PubMed Abstract](#)
 26. La P, Silva AC, Hou Z, *et al.*: Direct binding of DNA by tumor suppressor menin. *J Biol Chem*. 2004; 279(47): 49045–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Hughes CM, Rozenblatt-Rosen O, Milne TA, *et al.*: Menin associates with a trithorax family histone methyltransferase complex and with the *hoxc8* locus. *Mol Cell*. 2004; 13(4): 587–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Huang J, Gurung B, Wan B, *et al.*: The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. *Nature*. 2012; 482(7386): 542–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. **F** Busygina V, Kottmann MC, Scott KL, *et al.*: Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. *Cancer Res*. 2006; 66(17): 8397–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 30. Agarwal SK, Guru SC, Heppner C, *et al.*: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. *Cell*. 1999; 96(1): 143–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Kaji H, Canaff L, Lebrun JJ, *et al.*: Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. *Proc Natl Acad Sci U S A*. 2001; 98(7): 3837–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. La P, Schnepf RW, Petersen C, *et al.*: Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. *Endocrinology*. 2004; 145(7): 3443–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Heppner C, Bilimoria KY, Agarwal SK, *et al.*: The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. *Oncogene*. 2001; 20(36): 4917–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Inoue Y, Hendy GN, Canaff L, *et al.*: Menin interacts with β -catenin in osteoblast differentiation. *Horm Metab Res*. 2011; 43(3): 183–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Imachi H, Murao K, Dobashi H, *et al.*: Menin, a product of the MEN1 gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. *Breast Cancer Res Treat*. 2010; 122(2): 395–407.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Dreijerink KM, Mulder KW, Winkler GS, *et al.*: Menin links estrogen receptor activation to histone H3K4 trimethylation. *Cancer Res*. 2006; 66(9): 4929–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Lopez-Egido J, Cunningham J, Berg M, *et al.*: Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. *Exp Cell Res*. 2002; 278(2): 175–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Wuescher L, Angevine K, Hinds T, *et al.*: Insulin regulates menin expression, cytoplasmic localization, and interaction with FOXO1. *Am J Physiol Endocrinol Metab*. 2011; 301(3): E474–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Wang Y, Ozawa A, Zaman S, *et al.*: The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. *Cancer Res*. 2011; 71(2): 371–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Kim YS, Burns AL, Goldsmith PK, *et al.*: Stable overexpression of MEN1 suppresses tumorigenicity of RAS. *Oncogene*. 1999; 18(43): 5936–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Ratineau C, Bernard C, Poncet G, *et al.*: Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells. *J Biol Chem*. 2004; 279(23): 24477–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Schnepf RW, Hou Z, Wang H, *et al.*: Functional interaction between tumor suppressor menin and activator of S-phase kinase. *Cancer Res*. 2004; 64(18): 6791–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Schnepf RW, Mao H, Sykes SM, *et al.*: Menin induces apoptosis in murine embryonic fibroblasts. *J Biol Chem*. 2004; 279(11): 10685–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Sayo Y, Murao K, Imachi H, *et al.*: The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. *Endocrinology*. 2002; 143(6): 2437–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Busygina V, Suphacheetiporn K, Marek LR, *et al.*: Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. *Hum Mol Genet*. 2004; 13(20): 2399–408.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Milne TA, Hughes CM, Lloyd R, *et al.*: Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. *Proc Natl Acad Sci U S A*. 2005; 102(3): 749–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Yokoyama A, Wang Z, Wysocka J, *et al.*: Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. *Mol Cell Biol*. 2004; 24(13): 5639–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Li BE, Ernst P: Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. *Exp Hematol*. 2014; 42(12): 995–1012.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Yokoyama A, Somervaille TC, Smith KS, *et al.*: The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. *Cell*. 2005; 123(2): 207–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Okada Y, Feng Q, Lin Y, *et al.*: hDOT1L links histone methylation to leukemogenesis. *Cell*. 2005; 121(2): 167–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. **F** Daffon C, Craig VJ, Méreau H, *et al.*: Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. *Leukemia*. 2017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. Thakker RV: Multiple endocrine neoplasia type 1. *Indian J Endocrinol Metab*. 2012; 16(Suppl 2): S272–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. **F** Marini F, Giusti F, Brandi ML: Genetic test in multiple endocrine neoplasia type 1 syndrome: An evolving story. *World J Exp Med*. 2015; 5(2): 124–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 54. Marini F, Carbonell Sala S, Falchetti A, *et al.*: The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis.

- J Endocrinol Invest.* 2008; **31**(10): 905–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Lemos MC, Thakker RV: **Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.** *Hum Mutat.* 2008; **29**(1): 22–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 56. **The UMD- MEN1 mutations database.**
[Reference Source](#)
 57. Agarwal SK, Kester MB, Debelenko LV, *et al.*: **Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states.** *Hum Mol Genet.* 1997; **6**(7): 1169–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Bassett JH, Forbes SA, Pannett AA, *et al.*: **Characterization of mutations in patients with multiple endocrine neoplasia type 1.** *Am J Hum Genet.* 1998; **62**(2): 232–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. **F** Thakker RV: **Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).** *Mol Cell Endocrinol.* 2014; **386**(1–2): 2–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 60. **F** Laitman Y, Jaffe A, Schayek H, *et al.*: **De novo mutation in MEN1 is not associated with parental somatic mosaicism.** *Endocr Relat Cancer.* 2017; **24**(1): L1–L3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 61. Karges W, Jostardt K, Maier S, *et al.*: **Multiple endocrine neoplasia type 1 (MEN1) gene mutations in a subset of patients with sporadic and familial primary hyperparathyroidism target the coding sequence but spare the promoter region.** *J Endocrinol.* 2000; **166**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Turner JJ, Christie PT, Pearce SH, *et al.*: **Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1).** *Hum Mutat.* 2010; **31**(1): E1089–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Kouvaraki MA, Lee JE, Shapiro SE, *et al.*: **Genotype-phenotype analysis in multiple endocrine neoplasia type 1.** *Arch Surg.* 2002; **137**(6): 641–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Bartsch DK, Langer P, Wild A, *et al.*: **Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?** *Surgery.* 2000; **128**(6): 958–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Namiura H, Sato M, Miyauchi A, *et al.*: **Different phenotypes of multiple endocrine neoplasia type 1 (MEN1) in monozygotic twins found in a Japanese MEN1 family with MEN1 gene mutation.** *Endocr J.* 2000; **47**(1): 37–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Concolino P, Rossodivita A, Carrozza C, *et al.*: **A novel MEN1 frameshift germline mutation in two Italian monozygotic twins.** *Clin Chem Lab Med.* 2008; **46**(6): 824–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Carty SE, Helm AK, Amico JA, *et al.*: **The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.** *Surgery.* 1998; **124**(6): 1106–13; discussion 1113–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Doherty GM, Olson JA, Frisella MM, *et al.*: **Lethality of multiple endocrine neoplasia type I.** *World J Surg.* 1998; **22**(6): 581–6; discussion 586–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Goudet P, Murat A, Binquet C, *et al.*: **Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.** *World J Surg.* 2010; **34**(2): 249–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Dean PG, van Heerden JA, Farley DR, *et al.*: **Are patients with multiple endocrine neoplasia type I prone to premature death?** *World J Surg.* 2000; **24**(11): 1437–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Pieterman CR, Schreinemakers JM, Koppeschaar HP, *et al.*: **Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome.** *Clin Endocrinol (Oxf).* 2009; **70**(4): 575–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Lourenço DM Jr, Toledo RA, Coutinho FL, *et al.*: **The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1.** *Clinics (Sao Paulo).* 2007; **62**(4): 465–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Ramundo V, Milone F, Severino R, *et al.*: **Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients.** *Horm Metab Res.* 2011; **43**(11): 794–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Thakker RV, Bouloux P, Wooding C, *et al.*: **Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11.** *N Engl J Med.* 1989; **321**(4): 218–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Pannett AA, Thakker RV: **Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis.** *J Clin Endocrinol Metab.* 2001; **86**(9): 4371–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Knudson AG Jr, Strong LC, Anderson DE: **Heredity and cancer in man.** *Prog Med Genet.* 1973; **9**: 113–58.
[PubMed Abstract](#)
 77. Lips CJ, Dreijerink KM, Höppener JW: **Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation.** *Clinics (Sao Paulo).* 2012; **67**(Suppl 1): 49–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. **F** Longuini VC, Lourenço DM Jr, Sekiya T, *et al.*: **Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations.** *Eur J Endocrinol.* 2014; **171**(3): 335–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 79. Luzi E, Marini F, Giusti F, *et al.*: **The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit".** *PLoS One.* 2012; **7**(6): e39767.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. **F** Circelli L, Ramundo V, Marotta V, *et al.*: **Prognostic role of the CDKN1B V109G polymorphism in multiple endocrine neoplasia type 1.** *J Cell Mol Med.* 2015; **19**(7): 1735–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 81. **F** LeBlanc VG, Marra MA: **Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?** *Cancers (Basel).* 2015; **7**(3): 1925–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 82. **F** Abel HJ, Al-Kateb H, Cottrell CE, *et al.*: **Detection of gene rearrangements in targeted clinical next-generation sequencing.** *J Mol Diagn.* 2014; **16**(4): 405–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 83. **F** Acuna-Hidalgo R, Veltman JA, Hoischen A: **New insights into the generation and role of de novo mutations in health and disease.** *Genome Biol.* 2016; **17**(1): 241.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 84. **F** Bongiovanni M, Trimboli P, Rossi ED, *et al.*: **DIAGNOSIS OF ENDOCRINE DISEASE: High-yield thyroid fine-needle aspiration cytology: an update focused on ancillary techniques improving its accuracy.** *Eur J Endocrinol.* 2016; **174**(2): R53–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 85. **F** Forlenza GP, Calhoun A, Beckman KB, *et al.*: **Next generation sequencing in endocrine practice.** *Mol Genet Metab.* 2015; **115**(2–3): 61–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 86. Thakker RV, Newey PJ, Walls GV, *et al.*: **Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).** *J Clin Endocrinol Metab.* 2012; **97**(9): 2990–3011.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Arundhati Sharma**

All India Institute of Medical Sciences, New Delhi, New Delhi, India

Competing Interests: No competing interests were disclosed.

2. **Eitan Friedman**

¹ Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel

² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Competing Interests: No competing interests were disclosed.

3. **Antongiulio Faggiano**

University of Naples Federico II, Naples, Italy

Annamaria Colao

University of Naples Federico II, Naples, Italy

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research